(-)-DHMEQ
| Title | Journal |
|---|---|
| Exposure to a combination of formaldehyde and DINP aggravated asthma-like pathology through oxidative stress and NF-κB activation. | Toxicology 20180701 |
| Ligand-dependent EGFR activation induces the co-expression of IL-6 and PAI-1 via the NFkB pathway in advanced-stage epithelial ovarian cancer. | Oncogene 20120913 |
| The novel NF-κB inhibitor DHMEQ synergizes with celecoxib to exert antitumor effects on human liver cancer cells by a ROS-dependent mechanism. | Cancer letters 20120901 |
| Enhancement of radiosensitivity by a unique novel NF-κB inhibitor, DHMEQ, in prostate cancer. | British journal of cancer 20120807 |
| Dehydroxymethylepoxyquinomicin (DHMEQ), a novel NF-kappaB inhibitor, inhibits allergic inflammation and airway remodelling in murine models of asthma. | Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology 20120801 |
| Inhibition of nuclear factor-κB by dehydroxymethylepoxyquinomicin induces schedule-dependent chemosensitivity to anticancer drugs and enhances chemoinduced apoptosis in osteosarcoma cells. | Anti-cancer drugs 20120701 |
| Involvement of NF-κB-mediated expression of galectin-3-binding protein in TNF-α-induced breast cancer cell adhesion. | Oncology reports 20120601 |
| Immunomodulatory effect of nuclear factor-κB inhibition by dehydroxymethylepoxyquinomicin in combination with donor-specific blood transfusion. | Transplantation 20120427 |
| Involvement of DNA binding domain in the cellular stability and importin affinity of NF-κB component RelB. | Organic & biomolecular chemistry 20120421 |
| A novel NF-κB inhibitor, dehydroxymethylepoxyquinomicin, ameliorates inflammatory colonic injury in mice. | Journal of Crohn's & colitis 20120301 |
| Antitumor effect of dehydroxymethylepoxyquinomicin, a small molecule inhibitor of nuclear factor-κB, on glioblastoma. | Neuro-oncology 20120101 |
| Suppression of inflammatory cytokine secretion by an NF-ĸB inhibitor DHMEQ in nasal polyps fibroblasts. | Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology 20120101 |
| A chemo-enzymatic expeditious route to racemic dihexanoyl (2R*,3R*,4R*)-dehydroxymethylepoxyquinomycin (DHMEQ), the precursor for lipase-catalyzed synthesis of the potent nuclear factor-κB inhibitor, (2S,3S,4S)-DHMEQ. | Chemical & pharmaceutical bulletin 20120101 |
| Bioimaging analysis of nuclear factor-κB activity in Philadelphia chromosome-positive acute lymphoblastic leukemia cells reveals its synergistic upregulation by tumor necrosis factor-α-stimulated changes to the microenvironment. | Cancer science 20111101 |
| Design and synthesis of biotinylated DHMEQ for direct identification of its target NF-κB components. | Bioorganic & medicinal chemistry letters 20111101 |
| Dehydroxymethylepoxyquinomicin (DHMEQ) can suppress tumour necrosis factor-α production in lipopolysaccharide-injected mice, resulting in rescuing mice from death in vivo. | Clinical and experimental immunology 20111101 |
| Possible role of peritoneal NF-κB in peripheral inflammation and cancer: lessons from the inhibitor DHMEQ. | Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 20110701 |
| Chemoenzymatic synthesis of (2R,3R,4R)-dehydroxymethylepoxyquinomicin (DHMEQ), a new activator of antioxidant transcription factor Nrf2. | Organic & biomolecular chemistry 20110621 |
| [NF-kappaB inhibitor]. | Nihon rinsho. Japanese journal of clinical medicine 20110601 |
| Inhibition of nuclear factor-kappaB suppresses peritoneal dissemination of gastric cancer by blocking cancer cell adhesion. | Cancer science 20110501 |
| Anti-tumor activity of dehydroxymethylepoxyquinomicin against human oral squamous cell carcinoma cell lines in vitro and in vivo. | Oral oncology 20110501 |
| Inhibition of immune activation by a novel nuclear factor-kappa B inhibitor in HTLV-I-associated neurologic disease. | Blood 20110324 |
| Apoptosis in mouse amniotic epithelium is induced by activated macrophages through the TNF receptor type 1/TNF pathway. | Biology of reproduction 20110201 |
| Hydrogen and N-acetyl-L-cysteine rescue oxidative stress-induced angiogenesis in a mouse corneal alkali-burn model. | Investigative ophthalmology & visual science 20110121 |
| Coffee induces breast cancer resistance protein expression in Caco-2 cells. | Biological & pharmaceutical bulletin 20110101 |
| The side population, as a precursor of Hodgkin and Reed-Sternberg cells and a target for nuclear factor-κB inhibitors in Hodgkin's lymphoma. | Cancer science 20101101 |
| A new NF-κB inhibitor based on the amino-epoxyquinol core of DHMEQ. | Bioorganic & medicinal chemistry letters 20101001 |
| Donor pretreatment with DHMEQ improves islet transplantation. | The Journal of surgical research 20100901 |
| Topical application of dehydroxymethylepoxyquinomicin improves allergic inflammation via NF-kappaB inhibition. | The Journal of allergy and clinical immunology 20100801 |
| Dehydroxymethylepoxyquinomicin, a novel nuclear factor-kappaB inhibitor, prevents inflammatory injury induced by interferon-gamma and histamine in NCTC 2544 keratinocytes. | Clinical and experimental pharmacology & physiology 20100701 |
| Inhibition of active HIV-1 replication by NF-kappaB inhibitor DHMEQ. | Microbes and infection 20100501 |
| Characterizing the involvement of the nuclear factor-kappa B (NF kappa B) transcription factor in uveal melanoma. | Investigative ophthalmology & visual science 20100401 |
| Amelioration of experimental autoimmune uveoretinitis with nuclear factor-{kappa}B Inhibitor dehydroxy methyl epoxyquinomicin in mice. | Investigative ophthalmology & visual science 20100401 |
| Potent cytotoxic effect of a novel nuclear factor-kappaB inhibitor dehydroxymethylepoxyquinomicin on human bladder cancer cells producing various cytokines. | Urology 20100401 |
| Gene set enrichment analysis provides insight into novel signalling pathways in breast cancer stem cells. | British journal of cancer 20100105 |
| A small molecule inhibitor of NF-kappaB, dehydroxymethylepoxyquinomicin (DHMEQ), suppresses growth and invasion of nasopharyngeal carcinoma (NPC) cells. | Cancer letters 20100101 |
| Dehydroxymethylepoxyquinomicin inhibits expression and production of inflammatory mediators in interleukin-1beta-induced human chondrocytes. | Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology 20100101 |
| Efficient cellular uptake of the novel NF-kappaB inhibitor (-)-DHMEQ and irreversible inhibition of NF-kappaB in neoplastic cells. | Oncology research 20100101 |
| Induction of oncogene addiction shift to NF-kappaB by camptothecin in solid tumor cells. | Biochemical and biophysical research communications 20091204 |
| Efficient synthesis of (+/-)-parasitenone, a novel inhibitor of NF-kappaB. | Bioorganic & medicinal chemistry letters 20090915 |
| Unusual intramolecular N-->O acyl group migration occurring during conjugation of (-)-DHMEQ with cysteine. | Bioorganic & medicinal chemistry letters 20090915 |
| Impairment of plasmacytoid dendritic cells for IFN production by the ligand for immunoglobulin-like transcript 7 expressed on human cancer cells. | Clinical cancer research : an official journal of the American Association for Cancer Research 20090915 |
| Possible involvement of chemokine-induced platelet activation in thrombophilic diathesis of antiphospholipid syndrome. | Annals of the New York Academy of Sciences 20090901 |
| Antitumor effects of dehydroxymethylepoxyquinomicin, a novel nuclear factor-kappaB inhibitor, in human liver cancer cells are mediated through a reactive oxygen species-dependent mechanism. | Molecular pharmacology 20090801 |
| Inhibition of inflammatory mediator secretion by (-)-DHMEQ in mouse bone marrow-derived macrophages. | Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 20090601 |
| Transient inhibition of NF-kappaB by DHMEQ induces cell death of primary effusion lymphoma without HHV-8 reactivation. | Cancer science 20090401 |
| Induction of histidine decarboxylase in macrophages inhibited by the novel NF-kappaB inhibitor (-)-DHMEQ. | Biochemical and biophysical research communications 20090206 |
| Chemosensitization and immunosensitization of resistant cancer cells to apoptosis and inhibition of metastasis by the specific NF-kappaB inhibitor DHMEQ. | Current pharmaceutical design 20090101 |
| Growth suppression and apoptosis induction in synovial sarcoma cell lines by a novel NF-kappaB inhibitor, dehydroxymethylepoxyquinomicin (DHMEQ). | Cancer letters 20081218 |
| Identification of the RelA domain responsible for action of a new NF-kappaB inhibitor DHMEQ. | Biochemical and biophysical research communications 20081114 |
| Dehydroxymethylepoxyquinomicin, a novel nuclear Factor-kappaB inhibitor, enhances antitumor activity of taxanes in anaplastic thyroid cancer cells. | Endocrinology 20081101 |
| The NF-kappaB inhibitors (bortezomib and DHMEQ) sensitise rituximab-resistant AIDS-B-non-Hodgkin lymphoma to apoptosis by various chemotherapeutic drugs. | Leukemia & lymphoma 20081001 |
| Inactivation of NF-kappaB components by covalent binding of (-)-dehydroxymethylepoxyquinomicin to specific cysteine residues. | Journal of medicinal chemistry 20080925 |
| DHMEQ, a novel NF-kappaB inhibitor, suppresses growth and type I collagen accumulation in keloid fibroblasts. | Journal of dermatological science 20080901 |
| The novel NF-kappaB inhibitor, dehydroxymethylepoxyquinomicin, prevents local and remote organ injury following intestinal ischemia/reperfusion in rats. | The Journal of surgical research 20080901 |
| A simple and reliable method for determining plasma concentration of dehydroxymethylepoxyquinomicin by high performance liquid chromatography with mass spectrometry. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20080801 |
| DHMEQ, a novel nuclear factor-kappaB inhibitor, induces selective depletion of alloreactive or phytohaemagglutinin-stimulated peripheral blood mononuclear cells, decreases production of T helper type 1 cytokines, and blocks maturation of dendritic cells. | Immunology 20080601 |
| Induction of apoptosis in Epstein-Barr virus-infected B-lymphocytes by the NF-kappaB inhibitor DHMEQ. | Microbes and infection 20080601 |
| Effects of DHMEQ, a novel nuclear factor-kappab inhibitor, on beta cell dysfunction in INS-1 cells. | Endocrine journal 20080501 |
| The novel NF-kappaB activation inhibitor dehydroxymethyl-epoxyquinomicin suppresses anti-Thy1.1-induced glomerulonephritis in rats. | Nephron. Experimental nephrology 20080101 |
| Dehydroxymethylepoxyquinomicin (DHMEQ) therapy reduces tumor formation in mice inoculated with tax-deficient adult T-cell leukemia-derived cell lines. | Cancer letters 20071118 |
| Targeting NF-kappaB and induction of apoptosis by novel NF-kappaB inhibitor dehydroxymethylepoxyquinomicin (DHMEQ) in Burkitt lymphoma cells. | Leukemia research 20071101 |
| [Screening of bioactive metabolites that suppress inflammation]. | Tanpakushitsu kakusan koso. Protein, nucleic acid, enzyme 20071001 |
| Suppression of diabetes-induced retinal inflammation by blocking the angiotensin II type 1 receptor or its downstream nuclear factor-kappaB pathway. | Investigative ophthalmology & visual science 20070901 |
| Nuclear factor-kB in thyroid carcinogenesis and progression: a novel therapeutic target for advanced thyroid cancer. | Arquivos brasileiros de endocrinologia e metabologia 20070701 |
| IkappaBalpha independent induction of NF-kappaB and its inhibition by DHMEQ in Hodgkin/Reed-Sternberg cells. | Laboratory investigation; a journal of technical methods and pathology 20070401 |
| Reversal of resistance to cytotoxic cancer therapies: DHMEQ as a chemo-sensitizing and immuno-sensitizing agent. | Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy 20070101 |
| NF-kappaB inhibitor dehydroxymethylepoxyquinomicin suppresses osteoclastogenesis and expression of NFATc1 in mouse arthritis without affecting expression of RANKL, osteoprotegerin or macrophage colony-stimulating factor. | Arthritis research & therapy 20070101 |
| Control of allograft rejection by applying a novel nuclear factor-kappaB inhibitor, dehydroxymethylepoxyquinomicin. | Transplantation 20061227 |
| A selective NFkappaB inhibitor, DHMEQ, reduced atherosclerosis in ApoE-deficient mice. | Journal of atherosclerosis and thrombosis 20061201 |
| [Clinical and hematological characteristics of adult T-cell leukemia/lymphoma]. | [Rinsho ketsueki] The Japanese journal of clinical hematology 20061201 |
| Inhibition of macrophage activation and phagocytosis by a novel NF-kappaB inhibitor, dehydroxymethylepoxyquinomicin. | Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 20061101 |
| Significance of autologous interleukin-6 production in the HA22T/VGH cell model of hepatocellular carcinoma. | Annals of the New York Academy of Sciences 20061101 |
| Inhibition of tumor growth by NF-kappaB inhibitors. | Cancer science 20061001 |
| DHMEQ, a novel NF-kappaB inhibitor, induces apoptosis and cell-cycle arrest in human hepatoma cells. | International journal of oncology 20060901 |
| DHMEQ, a new NF-kappaB inhibitor, induces apoptosis and enhances fludarabine effects on chronic lymphocytic leukemia cells. | Leukemia 20060501 |
| Blocking NF-kappaB as a potential strategy to treat adult T-cell leukemia/lymphoma. | Drug news & perspectives 20060501 |
| Survivin associates with cell proliferation in renal cancer cells: regulation of survivin expression by insulin-like growth factor-1, interferon-gamma and a novel NF-kappaB inhibitor. | International journal of oncology 20060401 |
| Antitumor effects of the novel NF-kappaB inhibitor dehydroxymethyl-epoxyquinomicin on human hepatic cancer cells: analysis of synergy with cisplatin and of possible correlation with inhibition of pro-survival genes and IL-6 production. | International journal of oncology 20060401 |
| Effects of a novel NF-kappaB inhibitor, dehydroxymethylepoxyquinomicin (DHMEQ), on growth, apoptosis, gene expression, and chemosensitivity in head and neck squamous cell carcinoma cell lines. | Head & neck 20060201 |
| In vitro and in vivo antitumor activity of the NF-kappaB inhibitor DHMEQ in the human T-cell leukemia virus type I-infected cell line, HUT-102. | Leukemia research 20060101 |
| Enhancement of the caspase-independent apoptotic sensitivity of pancreatic cancer cells by DHMEQ, an NF-kappaB inhibitor. | International journal of oncology 20051101 |
| Dual targeting of transformed and untransformed HTLV-1-infected T cells by DHMEQ, a potent and selective inhibitor of NF-kappaB, as a strategy for chemoprevention and therapy of adult T-cell leukemia. | Blood 20051001 |
| In vivo antitumor activity of the NF-kappaB inhibitor dehydroxymethylepoxyquinomicin in a mouse model of adult T-cell leukemia. | Carcinogenesis 20050801 |
| Prevention of cancer cachexia by a novel nuclear factor {kappa}B inhibitor in prostate cancer. | Clinical cancer research : an official journal of the American Association for Cancer Research 20050801 |
| Inhibition of inflammatory cytokine secretion from mouse microglia cells by DHMEQ, an NF-kappaB inhibitor. | Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 20050701 |
| Dehydroxymethylepoxyquinomicin, a novel nuclear factor-kappaB inhibitor, induces apoptosis in multiple myeloma cells in an IkappaBalpha-independent manner. | Molecular cancer therapeutics 20050701 |
| Inhibition of RANKL-induced osteoclastogenesis by (-)-DHMEQ, a novel NF-kappaB inhibitor, through downregulation of NFATc1. | Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20050401 |
| A novel NF-kappaB inhibitor DHMEQ selectively targets constitutive NF-kappaB activity and induces apoptosis of multiple myeloma cells in vitro and in vivo. | International journal of cancer 20050310 |
| Targeting of nuclear factor kappaB Pathways by dehydroxymethylepoxyquinomicin, a novel inhibitor of breast carcinomas: antitumor and antiangiogenic potential in vivo. | Clinical cancer research : an official journal of the American Association for Cancer Research 20050201 |
| Effect of a small molecule inhibitor of nuclear factor-kappaB nuclear translocation in a murine model of arthritis and cultured human synovial cells. | Arthritis research & therapy 20050101 |
| Inhibition of cellular adhesion in human umbilical vein endothelial cells by NF-kappaB inhibitor DHMEQ under flow. | Oncology research 20050101 |
| Induction of thyroid cancer cell apoptosis by a novel nuclear factor kappaB inhibitor, dehydroxymethylepoxyquinomicin. | Clinical cancer research : an official journal of the American Association for Cancer Research 20041015 |
| Antitumor effect of a novel nuclear factor-kappa B activation inhibitor in bladder cancer cells. | Expert review of anticancer therapy 20031201 |
| Novel nuclear factor kappa B activation inhibitor prevents inflammatory injury in unilateral ureteral obstruction. | The Journal of urology 20030401 |
| Suppression of hormone-refractory prostate cancer by a novel nuclear factor kappaB inhibitor in nude mice. | Cancer research 20030101 |
| Preparation of radioactively labeled dehydroxymethyl-epoxyquinomicin, an NF-kappa B function inhibitor. | Drugs under experimental and clinical research 20030101 |
| Synthesis and structure-activity relationship of dehydroxymethylepoxyquinomicin analogues as inhibitors of NF-kappaB functions. | Bioorganic & medicinal chemistry 20021201 |
| Molecular design and biological activities of NF-kappaB inhibitors. | Molecules and cells 20021031 |
| Inhibition of tumor necrosis factor-alpha -induced nuclear translocation and activation of NF-kappa B by dehydroxymethylepoxyquinomicin. | The Journal of biological chemistry 20020705 |